Videos

O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.

Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.

O’Donoghue discusses the results of the recent OCEAN(a)-DOSE trial and addresses the implications for Lp(a)-lowering therapies moving forward.

Kirkorian speaks in this interview about her sessions at SDPA Fall on genetic disorders in pediatric dermatology patients.

Halpin reviews the state of triple therapy inhaler prescribing strategies in the era of new biologic options.

Soong discussed the role of allergist's in atopic dermatitis care at a recent HCPLive clinical forum.

Explore the long-term safety and efficacy of JAK inhibitors in atopic dermatitis, enhancing patient care and clinician confidence.

Healthcare providers discuss the importance of effective communication when switching patients from biologics to JAK inhibitors.

Clinicians discuss the importance of patient-centered treatment decisions and the need to address therapeutic inertia in managing chronic conditions.

Healthcare professionals explore effective questioning techniques to uncover deeper emotional and physical impacts of skin pain in patients.

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Experts discuss the future of psoriasis treatment, highlighting the potential of oral therapies to enhance patient adherence and quality of life.

Explore the complexities of psoriasis treatment, including advanced therapies, mechanisms of action, and the potential of molecular testing for personalized care.

CAVT effectively reduced right-to-left ventricular diameter ratio within 48 hours, with earlier vital sign normalizing and similar adverse event rates to AC.

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Nicholls highlights tirzepatide’s capacity to lower the risk of heart failure mortality, as well as hospitalizations or urgent visits.

In her SDPA Fall Dermatology Conference interview, Holzem highlights key warning signs for a variety of dermatologic conditions requiring hospital admission.

This interview at the SDPA Fall Dermatology Conference highlights several topics covered in sessions presented by Trotter.

Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.

This interview at SDPA highlights Gatti's views on the impact of technology on radiology, pathology, and dermatology.

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Gill describes tegoprubart’s efficacy and safety for post-kidney transplant immunosuppression and reviews key phase 2 BESTOW trial data from ASN.

ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.

At ACAAI 2025, Manning highlighted sustained attack reduction and strong patient preference for donidalorsen across long-term and switch data.

Bhatt discusses the positive results from the phase 2 trial of quarterly and monthly doses of investigational IL-6 inhibitor pacibekitug.

Alkhouri explains the importance of differentiating F3 from cirrhosis and the utility of different noninvasive tests for identifying these patients.

A study presented at ACAAI 2025 reveals HAE attacks may start in toddlers, highlighting significant daily burdens and the importance of timely diagnosis and treatment.

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.